Breakout Sessions

 

Breakout Session 1

Digital Therapeutics – challenges & opportunities

Digital Therapeutics Solutions are evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. Such treatments have made a big leap forward in recent years. In this session Digital Therapeutics and its challenges and opportunities will be discussed from three different angles. A startup will show how an agile small company can bring value in such a complex field. A professor from the university will explain how new treatments based on circadian rhythms have been developed over the years and how challenging the development of such treatments can be. A large pharmaceutical company will show how a global leading company views the developments in this area and predicts where the journey will go.

Dr Thomas Guggi, digital Therapeutix Ltd

Prof Francis Levi, Professor of Biomedicine

Andrew Koubatis, Altran

Panos Papakonstantinou, Novartis

CTO, Altran Switzerland

Breakout Session 2

The startup dilemma – how to find investors and how to compellingly attract strategic industrial partners?

In their pursuit of business success, startups must navigate their way through much unknown territory. One of the biggest challenges is to find and attract suitable investors. In addition to securing funding, it is also advantageous to appeal to strategic partners who can assist with corporate development in national and international markets (particularly concerning industrialization and international sales) and then convince them to support the planned strategies. Following an introductory presentation, three investors / strategic partners and two startups will share their personal experiences and best practices. The session will be rounded up with a panel discussion involving the speakers, as well as the audience.

Penny Schiffer, Raized.ai AG

Adrian Stolz, Credit Suisse (Schweiz) AG

Patrick Griss, Zühlke Ventures AG

Reto Hertler, Wille Finance AG

Ronja Bruhn, STIMIT AG

Dr Stefan Tuchschmid, VirtaMed AG

Keynotes

  • What investment opportunities exist for Medtech startups and how to get them? - Penny Schiffer

  • Financing Swiss startups: Challenges from a growth fund perspective - Adrian Stolz

  • Wishes and requirements for startups for a successful investment round - Patrick Griss and Reto Hertler

  • How to navigate through a world of opportunities, and decide which partners and investors fit best to YOU? A navigation guide - Ronja Bruhn

  • How to decide which investors are the right ones and how to rech them? A Best Practice report - Dr Stefan Tuchschmid

Head Life Science, be-advanced AG

 

Breakout Session 3

Current Research Trends

Recent technological phenomena such as Medical Big Data or the Internet of Things influence research in the field of biomedical engineering - bringing forth innovative products and generating new business processes. Miniaturization is one of the significant research areas, and biologically enriched medical devices is another. Leading experts will use the Breakout Session to illustrate where the journey leads from a research point of view and introduce the most impactful developments - with a focus on medical technology and information from the field of biomaterials.

Dr Volker Koch, Bern University of Applied Sciences

Dr Janine Conde, Dentsply Sirona 

Dr med Andreas Häberlin, ARTORG

Head of Institute, FHNW

 

Breakout Session 4

Artificial Intelligence & Medtech: between leaps in innovation and approval hurdles

Artificial Intelligence is a significant topic in the field of medical technology. While it is rapidly changing other industries, the use of Artificial Intelligence is only advancing slowly in the medtech environment. There are, however, a growing number of high-class decision makers in the industry who become more conscious of the chances and risks of AI-projects.


The goal of this session is to provide insights into the current status of Artificial Intelligence in the medtech industry and to provide concrete ideas how to tackle the approval hurdles in order to encourage companies to include AI-considerations in their product strategies.

Daniel Diezi, Zühlke Group AG

Kay-Uwe Clemens, Carl Zeiss Meditec

Dr Gabriel Krummenacher, Zühlke Group AG

Corne de Jong, Healios AG

Keynotes

  • How Carl Zeiss Meditec addresses AI in product strategies and related social responsability - Kay-Uwe Clemens

  • Developing and CE marking a novel digital biomarker for Multiple Sclerosis, a long and challenging journey - Corne de Jong

 
 

Breakout Session 5

Creating Value – Reduce to the Essentials

Innovative technologies in medtech target both clinical and health care needs. The solutions need to deliver value for the patients, users, hospitals, and payors. If this is considered early enough in the design process, it will also help reduce production costs in the long run. In this session we elaborate value creation pathways together with two startups who are both currently entering their respective markets.
Take Home Message: Stakeholder requirements create value along the R&D process, in Supply Chain Management, as well as by supporting marketable product claims. Benefit from the lessons learned by these two young companies regarding their challenges, experiences, and identified success factors.

Andy Tonazzi, konplan AG

Christian Calame, Naviswiss AG

Michael Friedrich, Distalmotion SA

Keynotes

  • Small, Simple, Affordable - Christian Calame

  • Distalmotion - Making Sense of Robotic Surgery - Michael Friedrich

Director R&D Innovation, DePuy Synthes

 

Breakout Session 6

Get your innovation off the ground

Innovation is key to a strong Swiss medtech industry and essential in order to master future challenges. Switzerland boasts first-class research institutions that develop new technologies every day. Innosuisse, the Swiss Innovation Agency, supports projects that are jointly implemented by the scientific community and industry. In this Breakout Session, Alex Dommann (Empa) and Andreas Hogg (Coat-X AG) present their collaborative project “Development of Innovative Composite Multilayers Encapsulation Solutions in Orthopaedic and Trauma Surgery” and participants will learn more about how Innosuisse’s funding works in practice.

Director, Innosuisse

Freiburgstrasse 3, 3010 Bern, Switzerland

smd@swiss-medtech.ch | Tel: +41 31 330 97 79

© 2020 by Swiss Medtech

Partner

Innosuisse Logo